UA48981C2 - Заміщені бензиламінопіперидини, фармацевтична композиція та спосіб лікування - Google Patents
Заміщені бензиламінопіперидини, фармацевтична композиція та спосіб лікуванняInfo
- Publication number
- UA48981C2 UA48981C2 UA98020924A UA98020924A UA48981C2 UA 48981 C2 UA48981 C2 UA 48981C2 UA 98020924 A UA98020924 A UA 98020924A UA 98020924 A UA98020924 A UA 98020924A UA 48981 C2 UA48981 C2 UA 48981C2
- Authority
- UA
- Ukraine
- Prior art keywords
- halo
- alkoxy
- alkyl
- substituted
- carbon atoms
- Prior art date
Links
- QACOELYINOMVBY-UHFFFAOYSA-N n-benzylpiperidin-1-amine Chemical class C=1C=CC=CC=1CNN1CCCCC1 QACOELYINOMVBY-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Chemical class 0.000 title 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 241000590002 Helicobacter pylori Species 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010042496 Sunburn Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 1
- 229940037467 helicobacter pylori Drugs 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Заміщені бензиламінопіперидини загальної формули (І): , Цей винахід пропонує сполуки формули (І) та їх фармацевтично прийнятні солі, де замісник R являє собою галоген-С1-С8-алкіл, галоген-С2-С8-алкеніл, галоген-С2-С8-алкініл або галоген-С1-С8-алкіл, заміщений гідрокси- або С1-С8-алкокси-групою; R1 являє собою атом водню, атом галогену або С1-С6-алкокси-групу; або R та R1 разом з двома атомами вуглецю, спільними для бензольного кільця й замісників R та R1, утворюють конденсований С4-С6-цикпоалкіл, де один атом вуглецю необов'язково замінений атомом кисню, і де один чи два атоми вуглецю необов'язково мають до п'яти замісників, що вибираються з атому галогену, С1-С6-алкілу та галоген-С1-С6-алкілу; Χ являє собою С1-С8-алкокси-, галоген-С1-С6-алкокси-, фенокси-групу або атом галогену; та Аr являє собою фенільну групу, необов'язково заміщену атомом галогену. Ці сполуки можуть використовуватись для лікування шлунково-кишкового розладу, розладу центральної нервової системи, запального захворювання, блювання, нетримання сечі, болю, мігрені, сонячної еритеми, хвороб, розладів та несприятливих станів, викликаних Helicobacter pylori, або розвитку кровоносних судин у ссавця, особливо у людини.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB9500683 | 1995-08-24 | ||
| PCT/IB1996/000572 WO1997008144A1 (en) | 1995-08-24 | 1996-06-10 | Substituted benzylaminopiperidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA48981C2 true UA48981C2 (uk) | 2002-09-16 |
Family
ID=11004362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA98020924A UA48981C2 (uk) | 1995-08-24 | 1996-06-10 | Заміщені бензиламінопіперидини, фармацевтична композиція та спосіб лікування |
Country Status (42)
| Country | Link |
|---|---|
| US (1) | US6506775B1 (uk) |
| EP (2) | EP1114817B1 (uk) |
| JP (1) | JP3084069B2 (uk) |
| KR (1) | KR100288673B1 (uk) |
| CN (1) | CN1153764C (uk) |
| AP (1) | AP643A (uk) |
| AR (1) | AR006305A1 (uk) |
| AT (2) | ATE258166T1 (uk) |
| AU (1) | AU702698B2 (uk) |
| BG (1) | BG64126B1 (uk) |
| BR (1) | BR9609989A (uk) |
| CA (1) | CA2227814C (uk) |
| CO (1) | CO4480738A1 (uk) |
| CZ (1) | CZ297543B6 (uk) |
| DE (2) | DE69631390T2 (uk) |
| DK (2) | DK0861235T3 (uk) |
| DZ (1) | DZ2086A1 (uk) |
| ES (2) | ES2211684T3 (uk) |
| HK (1) | HK1014935A1 (uk) |
| HR (1) | HRP960386B1 (uk) |
| HU (1) | HU225480B1 (uk) |
| IL (1) | IL119078A (uk) |
| IS (1) | IS1947B (uk) |
| MA (1) | MA23961A1 (uk) |
| MX (1) | MX9801467A (uk) |
| MY (1) | MY114800A (uk) |
| NO (1) | NO310720B1 (uk) |
| NZ (1) | NZ308207A (uk) |
| OA (1) | OA10666A (uk) |
| PE (2) | PE20010700A1 (uk) |
| PL (1) | PL186773B1 (uk) |
| PT (2) | PT861235E (uk) |
| RO (1) | RO119299B1 (uk) |
| RU (1) | RU2152930C2 (uk) |
| SI (2) | SI0861235T1 (uk) |
| SK (1) | SK282925B6 (uk) |
| TN (1) | TNSN96107A1 (uk) |
| TR (1) | TR199800300T1 (uk) |
| TW (1) | TW340842B (uk) |
| UA (1) | UA48981C2 (uk) |
| WO (1) | WO1997008144A1 (uk) |
| YU (1) | YU49122B (uk) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9706196A (es) * | 1996-08-14 | 1998-02-28 | Pfizer | Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p. |
| TW426667B (en) * | 1997-11-19 | 2001-03-21 | Pfizer | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists |
| US6777428B1 (en) | 1999-02-10 | 2004-08-17 | Eli Lilly And Company | 5-HT1f agonist |
| EE200100586A (et) * | 1999-05-06 | 2003-02-17 | Pfizer Products Inc. | Asendatud bensolaktaamühendid |
| RS49964B (sr) | 1999-05-17 | 2008-09-29 | Pfizer Products Inc., | Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli |
| AU775861B2 (en) | 1999-05-21 | 2004-08-19 | Pfizer Products Inc. | 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| JP2001172178A (ja) * | 1999-10-25 | 2001-06-26 | Pfizer Prod Inc | 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン |
| US20020049211A1 (en) * | 2000-09-06 | 2002-04-25 | Sobolov-Jaynes Susan Beth | Combination treatment for depression and anxiety |
| EP1192952A3 (en) * | 2000-09-28 | 2003-03-26 | Pfizer Products Inc. | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist |
| US6911544B2 (en) | 2002-10-23 | 2005-06-28 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine |
| CN1777584A (zh) | 2003-04-18 | 2006-05-24 | 伊莱利利公司 | 作为5－ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物 |
| CA2566920A1 (en) * | 2004-05-21 | 2005-12-01 | Pfizer Products Inc. | Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine |
| MX2007000428A (es) | 2004-07-15 | 2008-03-05 | Amr Technology Inc | Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina. |
| ES2382814T3 (es) | 2005-05-17 | 2012-06-13 | Merck Sharp & Dohme Ltd. | Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer |
| UA95454C2 (uk) | 2005-07-15 | 2011-08-10 | Амр Текнолоджи, Інк. | Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну |
| EP1940842B1 (en) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| AU2008204380B2 (en) | 2007-01-10 | 2013-08-15 | Msd Italia S.R.L. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
| AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
| JP5501227B2 (ja) | 2007-06-27 | 2014-05-21 | メルク・シャープ・アンド・ドーム・コーポレーション | ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体 |
| JP2011515343A (ja) | 2008-03-03 | 2011-05-19 | タイガー ファーマテック | チロシンキナーゼ阻害薬 |
| EP2264029A4 (en) | 2008-03-31 | 2011-08-24 | Kowa Co | 1,3-dihydroisobenzofuran DERIVATIVE |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| MX2011011901A (es) | 2009-05-12 | 2012-01-20 | Albany Molecular Res Inc | Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas. |
| KR20120023072A (ko) | 2009-05-12 | 2012-03-12 | 브리스톨-마이어스 스큅 컴퍼니 | （Ｓ）-7-（〔1,2,4〕트리아졸〔1,5-ａ〕피리딘-6-일）-4-（3,4-디클로로페닐）-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도 |
| MX2011011907A (es) | 2009-05-12 | 2012-01-20 | Albany Molecular Res Inc | 7-([1,2,4,]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2, 3,4-tetrahidroisoquinolina y uso de la misma. |
| MY174452A (en) | 2009-10-14 | 2020-04-19 | Schering Corp | Substituted piperidines that increase p53 activity and the uses thereof |
| US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
| WO2012018754A2 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| AU2011292261B2 (en) | 2010-08-17 | 2015-05-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| WO2012036997A1 (en) | 2010-09-16 | 2012-03-22 | Schering Corporation | Fused pyrazole derivatives as novel erk inhibitors |
| DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
| US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| IN2013MN02170A (uk) | 2011-04-21 | 2015-06-12 | Piramal Entpr Ltd | |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP2844261B1 (en) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| AU2013323508B2 (en) | 2012-09-28 | 2017-11-02 | Merck Sharp & Dohme Corp. | Novel compounds that are ERK inhibitors |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| AU2013352568B2 (en) | 2012-11-28 | 2019-09-19 | Merck Sharp & Dohme Llc | Compositions and methods for treating cancer |
| US8846657B2 (en) | 2012-12-20 | 2014-09-30 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3525785A4 (en) | 2016-10-12 | 2020-03-25 | Merck Sharp & Dohme Corp. | KDM5 INHIBITORS |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US12173026B2 (en) | 2018-08-07 | 2024-12-24 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232929A (en) * | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
| US5364943A (en) * | 1991-11-27 | 1994-11-15 | Pfizer Inc. | Preparation of substituted piperidines |
| CZ289960B6 (cs) * | 1991-03-26 | 2002-05-15 | Pfizer Inc. | Způsob přípravy substituovaných piperidinů |
| ES2092113T3 (es) * | 1991-06-20 | 1996-11-16 | Pfizer | Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno. |
| US5340826A (en) * | 1993-02-04 | 1994-08-23 | Pfizer Inc. | Pharmaceutical agents for treatment of urinary incontinence |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| EP0653208A3 (en) * | 1993-11-17 | 1995-10-11 | Pfizer | Substance P antagonists for the treatment or prevention of sunburn. |
| EP0655246A1 (en) * | 1993-11-30 | 1995-05-31 | Pfizer Inc. | Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria |
| EP0780375B1 (en) * | 1995-12-21 | 2002-09-11 | Pfizer Inc. | 3-((5-substituted benzyl)amino)-2-phenylpiperidines as substance p antagonists |
| US5990125A (en) | 1996-01-19 | 1999-11-23 | Pfizer Inc. | NK-1 receptor antagonists for the treatment of cancer |
-
1996
- 1996-06-04 TW TW085106675A patent/TW340842B/zh active
- 1996-06-10 EP EP01108350A patent/EP1114817B1/en not_active Expired - Lifetime
- 1996-06-10 PT PT96914375T patent/PT861235E/pt unknown
- 1996-06-10 JP JP09510015A patent/JP3084069B2/ja not_active Expired - Fee Related
- 1996-06-10 ES ES01108350T patent/ES2211684T3/es not_active Expired - Lifetime
- 1996-06-10 DK DK96914375T patent/DK0861235T3/da active
- 1996-06-10 SK SK207-98A patent/SK282925B6/sk not_active IP Right Cessation
- 1996-06-10 ES ES96914375T patent/ES2163017T3/es not_active Expired - Lifetime
- 1996-06-10 SI SI9630374T patent/SI0861235T1/xx unknown
- 1996-06-10 TR TR1998/00300T patent/TR199800300T1/xx unknown
- 1996-06-10 RU RU98102959/04A patent/RU2152930C2/ru not_active IP Right Cessation
- 1996-06-10 EP EP96914375A patent/EP0861235B1/en not_active Expired - Lifetime
- 1996-06-10 DE DE69631390T patent/DE69631390T2/de not_active Expired - Fee Related
- 1996-06-10 DK DK01108350T patent/DK1114817T3/da active
- 1996-06-10 AT AT01108350T patent/ATE258166T1/de not_active IP Right Cessation
- 1996-06-10 CN CNB961965037A patent/CN1153764C/zh not_active Expired - Fee Related
- 1996-06-10 BR BR9609989A patent/BR9609989A/pt not_active Application Discontinuation
- 1996-06-10 UA UA98020924A patent/UA48981C2/uk unknown
- 1996-06-10 CZ CZ0052198A patent/CZ297543B6/cs not_active IP Right Cessation
- 1996-06-10 KR KR1019980701310A patent/KR100288673B1/ko not_active IP Right Cessation
- 1996-06-10 AT AT96914375T patent/ATE208377T1/de not_active IP Right Cessation
- 1996-06-10 NZ NZ308207A patent/NZ308207A/en unknown
- 1996-06-10 PT PT01108350T patent/PT1114817E/pt unknown
- 1996-06-10 WO PCT/IB1996/000572 patent/WO1997008144A1/en active IP Right Grant
- 1996-06-10 RO RO98-00334A patent/RO119299B1/ro unknown
- 1996-06-10 HU HU9901159A patent/HU225480B1/hu not_active IP Right Cessation
- 1996-06-10 MX MX9801467A patent/MX9801467A/es active IP Right Grant
- 1996-06-10 AU AU57769/96A patent/AU702698B2/en not_active Ceased
- 1996-06-10 SI SI9630670T patent/SI1114817T1/xx unknown
- 1996-06-10 TN TNTNSN96107A patent/TNSN96107A1/fr unknown
- 1996-06-10 CA CA002227814A patent/CA2227814C/en not_active Expired - Fee Related
- 1996-06-10 PL PL96325332A patent/PL186773B1/pl not_active IP Right Cessation
- 1996-06-10 DE DE69616817T patent/DE69616817T2/de not_active Expired - Fee Related
- 1996-08-15 IL IL11907896A patent/IL119078A/xx not_active IP Right Cessation
- 1996-08-20 AR ARP960104045A patent/AR006305A1/es active IP Right Grant
- 1996-08-21 PE PE2001000276A patent/PE20010700A1/es not_active Application Discontinuation
- 1996-08-21 PE PE1996000625A patent/PE1398A1/es not_active Application Discontinuation
- 1996-08-21 DZ DZ960130A patent/DZ2086A1/fr active
- 1996-08-22 HR HR960386A patent/HRP960386B1/xx not_active IP Right Cessation
- 1996-08-23 YU YU47896A patent/YU49122B/sh unknown
- 1996-08-23 MA MA24339A patent/MA23961A1/fr unknown
- 1996-08-23 MY MYPI96003496A patent/MY114800A/en unknown
- 1996-08-24 AP APAP/P/1996/000850A patent/AP643A/en active
- 1996-08-26 CO CO96045248A patent/CO4480738A1/es unknown
-
1997
- 1997-12-30 IS IS4644A patent/IS1947B/is unknown
-
1998
- 1998-02-23 NO NO19980751A patent/NO310720B1/no unknown
- 1998-02-23 OA OA9800023A patent/OA10666A/en unknown
- 1998-02-27 BG BG102288A patent/BG64126B1/bg unknown
- 1998-12-30 HK HK98119203A patent/HK1014935A1/xx not_active IP Right Cessation
-
2000
- 2000-05-01 US US09/564,398 patent/US6506775B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA48981C2 (uk) | Заміщені бензиламінопіперидини, фармацевтична композиція та спосіб лікування | |
| CA2226292A1 (en) | Substituted benzolactam compounds as substance p antagonists | |
| MY120558A (en) | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists | |
| BR9503694A (pt) | Composto método para o tratamento de um mamifero e composição farmacêutica | |
| MY104335A (en) | 4-aminophridine deravatives | |
| EG20530A (en) | Process for preparing of phenoxyphenyl cyclopentenyl hydroxyureas | |
| HU9602725D0 (en) | Anti-helicobacter ester and carbamate derivatives of azolones | |
| PT780375E (pt) | 3-¬(benzilo substituido em 5)amino|-2-phenilpiperidinas como antagonistas da substancia p | |
| BR9704352A (pt) | Compostos tricíclicos de piperidinilamino como antagonistas da substáncia p | |
| AU2287499A (en) | Azetidinecarboxamide derivatives for treating cns disorders | |
| IL99434A0 (en) | 3-(1h-indazol-3-yl)-4-pyridinamines,a process and intermediates for their preparation and pharmaceutical compositions containing them | |
| JPS57144299A (en) | Novel manufacture of 17 alpha-hydroxy-17 beta- hydroxyacetylsteroid and corresponding intermediate therefrom | |
| NO20005551L (no) | 2"-deoksyhygromycinderivater | |
| TH28832B (th) | สารปะกอบเบนซิลอะมิโนไพเพอริดินที่ถูกแทนที่ | |
| ES2181387T3 (es) | Derivados de azetidinocarboxamida para el tratamiento de trastornos del sistema nervioso central. |